Compare Heron Therapeutics Inc (HRTX) vs Li Auto Inc (LI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Li Auto Inc — how do they compare? Heron Therapeutics Inc trades at $0.37 (market cap $74.04M), while Li Auto Inc trades at $11.36 (market cap $10.83B). The key difference: Li Auto Inc is far larger — about 146.3× Heron Therapeutics Inc's market cap, and Heron Therapeutics Inc is more actively traded (3,668,095 versus 2,002,427). Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and Li Auto Inc for 101 Days on average.
| HRTX | LI | |
|---|---|---|
Market Cap | $74.04M | $10.83B |
Volume | 3,668,095 | 2,002,427 |
Sector | Health | Consumer Cyclical |
52-Week High | $1.49 | $23.61 |
52-Week Low | $0.27 | $10.69 |
Typical Hold Time | 35 Days | 101 Days |
Enterprise Value | $180.78M | $258.87M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.39, up 17.58% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7 million but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings performance discussions.
The outlook is mixed: strong analyst support and technical momentum suggest potential upside, but persistent losses and high valuation ratios pose significant risks. Investment opportunity hinges on revenue growth translating to profitability, while key risks include execution challenges and competitive pressures in the biotechnology sector.
Li Auto (LI) trades at $10.90, near 52-week lows amid declining delivery volumes and negative earnings surprises. The stock shows bearish technical signals with oversold RSI levels, while fundamentals reveal revenue contraction from $144.5B (2024) to $112.3B (2025) and negative net margins. Recent vehicle launches (Li i9, MEGA) aim to counter competitive pressures in China's EV market, but cash flow trends show operational challenges with -$8.6B operating cash flow in 2025.
Outlook remains challenged by execution risks and market saturation, though analyst consensus target of $15.18 suggests 39% upside. Key risks include persistent cash burn, intense domestic competition, and macroeconomic headwinds. The valuation appears reasonable with P/S of 0.73, but profitability recovery is critical for sustained momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Li Auto Inc
Li Auto is a leading Chinese NEV manufacturer that designs, develops, manufactures, and sells premium smart NEVs. The company started volume production of its first model Li One in November 2019. The model is a six-seater, large, premium plug-in electric SUV equipped with a range extension system and advanced smart vehicle solutions. It sold over 90,000 EVs in 2021, accounting for about 2.7% of China's passenger new energy vehicle market. Beyond Li One, the company will expand its product line, including both BEVs and PHEVs, to target a broader consumer base.
Read more on LI →
